A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF)
Latest Information Update: 20 Apr 2026
At a glance
- Drugs Sotatercept (Primary)
- Indications Heart failure; Pulmonary arterial hypertension
- Focus Proof of concept; Therapeutic Use
- Acronyms CADENCE
- Sponsors Acceleron Pharma
Most Recent Events
- 15 Apr 2026 Status changed from active, no longer recruiting to completed.
- 29 Mar 2026 According to a Merck and Co media release, data from this trial were presented today in a late-breaking clinical trial presentation at the American College of Cardiologys Annual Scientific Session and Expo (ACC.26), simultaneously published in Circulation and featured as part of an ACC.26 press conference.
- 29 Mar 2026 Results presented in the Merck and Co media release.